{"id":190431,"date":"2026-08-07T12:16:41","date_gmt":"2026-08-07T06:46:41","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=190431"},"modified":"2026-08-07T12:16:43","modified_gmt":"2026-08-07T06:46:43","slug":"krebs-biochemicals-q1-results-fy27-loss-2-crore","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/krebs-biochemicals-q1-results-fy27-loss-2-crore\/","title":{"rendered":"Krebs Biochemicals Q1 FY27 Results: Revenue Rs 6 Cr, PAT Rs 2.00 Cr and Key Highlights"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Krebs Biochemicals Q1 FY27 results declared Aug 6, 2026. Revenue Rs 6 Cr (+27.42% YoY). Net Loss Rs 2.00 Cr (+53.33% YoY). CMP Rs 54.51 (+0.72%).<\/em><\/p>\n<p>Krebs Biochemicals Q1 FY27 results were announced on August 6, 2026, on a Standalone basis. Krebs Biochemicals Q1 FY27 results show revenue grew +27.42% year-on-year to Rs 6 Cr from Rs 5 Cr in Q1 FY26, reflecting sustained demand in the Chemicals segment.<\/p>\n<p>Operating profit improved +79.36% YoY to Rs -1 Cr from Rs -3 Cr, indicating stronger operational efficiency. The company reported a net loss of Rs 2.00 Cr in Q1 FY27, narrowing from a loss of Rs 5.00 Cr in Q1 FY26, indicating a gradual recovery trajectory. The quarterly numbers offer a detailed picture of how the company is navigating the current chemicals environment.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=krebs-biochemicals-q1-fy27\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/krebs-biochemicals-q1-results-fy27-loss-2-crore\/#Krebs_Biochemicals_Q1_FY27_Financial_Highlights\" title=\"Krebs Biochemicals Q1 FY27 Financial Highlights\">Krebs Biochemicals Q1 FY27 Financial Highlights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/krebs-biochemicals-q1-results-fy27-loss-2-crore\/#Krebs_Biochemicals_Q1_FY27_Performance_Analysis\" title=\"Krebs Biochemicals Q1 FY27 Performance Analysis\">Krebs Biochemicals Q1 FY27 Performance Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/krebs-biochemicals-q1-results-fy27-loss-2-crore\/#Key_Business_Factors_in_Krebs_Biochemicals_Q1_FY27_Results\" title=\"Key Business Factors in Krebs Biochemicals Q1 FY27 Results\">Key Business Factors in Krebs Biochemicals Q1 FY27 Results<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/krebs-biochemicals-q1-results-fy27-loss-2-crore\/#Revenue_Growth_Momentum_in_the_Chemicals_Segment\" title=\"Revenue Growth Momentum in the Chemicals Segment\">Revenue Growth Momentum in the Chemicals Segment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/krebs-biochemicals-q1-results-fy27-loss-2-crore\/#Operating_Margin_Expansion_Signals_Efficiency_Gains\" title=\"Operating Margin Expansion Signals Efficiency Gains\">Operating Margin Expansion Signals Efficiency Gains<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/krebs-biochemicals-q1-results-fy27-loss-2-crore\/#Net_Loss_and_Path_Toward_Profitability\" title=\"Net Loss and Path Toward Profitability\">Net Loss and Path Toward Profitability<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/krebs-biochemicals-q1-results-fy27-loss-2-crore\/#Dividend_Details\" title=\"Dividend Details\">Dividend Details<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/krebs-biochemicals-q1-results-fy27-loss-2-crore\/#FY27_Outlook_for_Krebs_Biochemicals\" title=\"FY27 Outlook for Krebs Biochemicals\">FY27 Outlook for Krebs Biochemicals<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/krebs-biochemicals-q1-results-fy27-loss-2-crore\/#Krebs_Biochemicals_Stock_Performance_After_Q1_FY27_Results\" title=\"Krebs Biochemicals Stock Performance After Q1 FY27 Results\">Krebs Biochemicals Stock Performance After Q1 FY27 Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/krebs-biochemicals-q1-results-fy27-loss-2-crore\/#Key_Risks_for_Krebs_Biochemicals\" title=\"Key Risks for Krebs Biochemicals\">Key Risks for Krebs Biochemicals<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/krebs-biochemicals-q1-results-fy27-loss-2-crore\/#Sector-Specific_Headwinds\" title=\"Sector-Specific Headwinds\">Sector-Specific Headwinds<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/krebs-biochemicals-q1-results-fy27-loss-2-crore\/#Valuation_and_Earnings_Risk\" title=\"Valuation and Earnings Risk\">Valuation and Earnings Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/krebs-biochemicals-q1-results-fy27-loss-2-crore\/#Operational_and_Financial_Risk\" title=\"Operational and Financial Risk\">Operational and Financial Risk<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/krebs-biochemicals-q1-results-fy27-loss-2-crore\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/krebs-biochemicals-q1-results-fy27-loss-2-crore\/#Frequently_Asked_Questions_on_Krebs_Biochemicals_Q1_FY27_Results\" title=\"Frequently Asked Questions on Krebs Biochemicals Q1 FY27 Results\">Frequently Asked Questions on Krebs Biochemicals Q1 FY27 Results<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/krebs-biochemicals-q1-results-fy27-loss-2-crore\/#When_were_Krebs_Biochemicals_Q1_FY27_results_declared\" title=\"When were Krebs Biochemicals Q1 FY27 results declared?\">When were Krebs Biochemicals Q1 FY27 results declared?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/krebs-biochemicals-q1-results-fy27-loss-2-crore\/#What_was_Krebs_Biochemicals_revenue_in_Q1_FY27\" title=\"What was Krebs Biochemicals revenue in Q1 FY27?\">What was Krebs Biochemicals revenue in Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/krebs-biochemicals-q1-results-fy27-loss-2-crore\/#What_was_Krebs_Biochemicals_PAT_in_Q1_FY27\" title=\"What was Krebs Biochemicals PAT in Q1 FY27?\">What was Krebs Biochemicals PAT in Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/krebs-biochemicals-q1-results-fy27-loss-2-crore\/#Did_Krebs_Biochemicals_declare_a_dividend_in_Q1_FY27\" title=\"Did Krebs Biochemicals declare a dividend in Q1 FY27?\">Did Krebs Biochemicals declare a dividend in Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/krebs-biochemicals-q1-results-fy27-loss-2-crore\/#What_is_the_FY27_outlook_for_Krebs_Biochemicals\" title=\"What is the FY27 outlook for Krebs Biochemicals?\">What is the FY27 outlook for Krebs Biochemicals?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/krebs-biochemicals-q1-results-fy27-loss-2-crore\/#How_did_the_Krebs_Biochemicals_stock_react_to_Q1_FY27_results\" title=\"How did the Krebs Biochemicals stock react to Q1 FY27 results?\">How did the Krebs Biochemicals stock react to Q1 FY27 results?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Krebs_Biochemicals_Q1_FY27_Financial_Highlights\"><\/span><strong>Krebs Biochemicals Q1 FY27 Financial Highlights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width: 100%; border-collapse: collapse; font-size: 14px;\">\n<thead>\n<tr style=\"background: #0A0E1A; color: #ffffff;\">\n<th style=\"padding: 10px; text-align: left; border: 1px solid #DDDDDD;\">Metric<\/th>\n<th style=\"padding: 10px; text-align: center; border: 1px solid #DDDDDD;\">Q1 FY27 (Rs Cr)<\/th>\n<th style=\"padding: 10px; text-align: center; border: 1px solid #DDDDDD;\">Q1 FY26 (Rs Cr)<\/th>\n<th style=\"padding: 10px; text-align: center; border: 1px solid #DDDDDD;\">YoY Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDDDDD;\">Krebs Biochemicals Revenue<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDDDDD;\">6<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDDDDD;\">5<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDDDDD; color: green;\">+27.42%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDDDDD;\">Operating Profit<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDDDDD;\">-1<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDDDDD;\">-3<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDDDDD; color: green;\">+79.36%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDDDDD;\">Net Profit (PAT)<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDDDDD;\">-2.00<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDDDDD;\">-5.00<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDDDDD; color: green;\">+53.33%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDDDDD;\">Reporting Basis<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDDDDD;\" colspan=\"3\">Standalone<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Krebs_Biochemicals_Q1_FY27_Performance_Analysis\"><\/span><strong>Krebs Biochemicals Q1 FY27 Performance Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for Live Data on This Stock<\/strong><\/a><\/p>\n<p>Krebs Biochemicals Q1 FY27 results reflect strong fundamentals across key financial parameters. Revenue momentum continued on a strong footing with the top line reaching Rs 6 Cr for the April to June 2026 quarter.<\/p>\n<p>Operating profit stood at Rs -1 Cr, expanding +79.36% YoY. Margin improvement signals better cost absorption and product mix optimisation.<\/p>\n<p>The net loss of Rs 2.00 Cr in Krebs Biochemicals Q1 FY27 results indicates that the turnaround is still in progress. Investors monitoring Krebs Biochemicals Q1 FY27 results will note this as a key milestone for FY27 tracking.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Business_Factors_in_Krebs_Biochemicals_Q1_FY27_Results\"><\/span><strong>Key Business Factors in Krebs Biochemicals Q1 FY27 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Revenue_Growth_Momentum_in_the_Chemicals_Segment\"><\/span><strong>Revenue Growth Momentum in the Chemicals Segment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Krebs Biochemicals Q1 FY27 results demonstrate consistent top-line expansion, with revenue rising +27.42% YoY to Rs 6 Cr. Volume-led growth and pricing discipline in key markets drove the uptick.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Operating_Margin_Expansion_Signals_Efficiency_Gains\"><\/span><strong>Operating Margin Expansion Signals Efficiency Gains<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Operating profit in Krebs Biochemicals Q1 FY27 results rose +79.36% YoY to Rs -1 Cr. This reflects tighter cost control, better product mix, and operating leverage as the company scales volumes in core business lines.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Net_Loss_and_Path_Toward_Profitability\"><\/span><strong>Net Loss and Path Toward Profitability<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Krebs Biochemicals Q1 FY27 results reflect a net loss of Rs 2.00 Cr. Management has outlined a roadmap to profitability through operational restructuring, debt reduction, and revenue scaling in higher-margin product lines.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Dividend_Details\"><\/span><strong>Dividend Details<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>No dividend was announced along with Krebs Biochemicals Q1 FY27 results. The company is likely retaining earnings for reinvestment into growth capex and working capital requirements.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"FY27_Outlook_for_Krebs_Biochemicals\"><\/span><strong>FY27 Outlook for Krebs Biochemicals<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Krebs Biochemicals is positioned to maintain growth momentum into Q2 FY27 and beyond, supported by order visibility, operational improvements, and sector tailwinds. Management guidance points toward continued expansion in the Chemicals business with a focus on margin improvement and market share consolidation. Investors tracking Krebs Biochemicals Q1 FY27 results are advised to consult a SEBI-registered financial advisor before making decisions.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Krebs_Biochemicals_Stock_Performance_After_Q1_FY27_Results\"><\/span><strong>Krebs Biochemicals Stock Performance After Q1 FY27 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Krebs Biochemicals live price and get daily stock recommendations.<\/em><\/p>\n<p>Krebs Biochemicals shares were trading higher at Rs 54.51 (+0.72%) on August 6, 2026, following the declaration of Krebs Biochemicals Q1 FY27 results. The stock reaction reflects investor sentiment on near-term earnings trajectory and sector outlook. CMP stood at Rs 54.51 on the results date, with a 52-week range reflecting the broader market sentiment toward the chemicals sector.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_for_Krebs_Biochemicals\"><\/span><strong>Key Risks for Krebs Biochemicals<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Sector-Specific_Headwinds\"><\/span><strong>Sector-Specific Headwinds<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Feedstock price volatility and Chinese competition in commodity chemicals remain risks.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Valuation_and_Earnings_Risk\"><\/span><strong>Valuation and Earnings Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Valuation risk remains if earnings growth fails to sustain at current levels over the next two to three quarters.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Operational_and_Financial_Risk\"><\/span><strong>Operational and Financial Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Working capital intensity and cash conversion cycle elongation pose risks to standalone cash flows.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Krebs Biochemicals Q1 FY27 results reflect near-term operational challenges with revenue at Rs 6 Cr and a net loss of Rs 2.00 Cr on a Standalone basis. The management&#8217;s ability to execute its recovery plan will determine the stock&#8217;s re-rating potential. Investors are advised to monitor quarterly progress before making investment decisions.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Krebs_Biochemicals_Q1_FY27_Results\"><\/span><strong>Frequently Asked Questions on Krebs Biochemicals Q1 FY27 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"When_were_Krebs_Biochemicals_Q1_FY27_results_declared\"><\/span><strong>When were Krebs Biochemicals Q1 FY27 results declared?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Krebs Biochemicals Q1 FY27 results were declared on August 6, 2026. The results cover the April to June 2026 quarter on a Standalone basis.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_Krebs_Biochemicals_revenue_in_Q1_FY27\"><\/span><strong>What was Krebs Biochemicals revenue in Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Krebs Biochemicals Q1 FY27 results show revenue of Rs 6 Cr, +27.42% compared to Rs 5 Cr in Q1 FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_Krebs_Biochemicals_PAT_in_Q1_FY27\"><\/span><strong>What was Krebs Biochemicals PAT in Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Net loss in Krebs Biochemicals Q1 FY27 results was Rs 2.00 Cr, +53.33% year-on-year.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Did_Krebs_Biochemicals_declare_a_dividend_in_Q1_FY27\"><\/span><strong>Did Krebs Biochemicals declare a dividend in Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No dividend was declared alongside Krebs Biochemicals Q1 FY27 results. Investors should check the official company announcements on BSE and NSE for any future dividend declarations.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_FY27_outlook_for_Krebs_Biochemicals\"><\/span><strong>What is the FY27 outlook for Krebs Biochemicals?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Krebs Biochemicals management has outlined a focus on revenue scaling and margin improvement for the remainder of FY27. Sector tailwinds and order book visibility will be key monitorables.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_did_the_Krebs_Biochemicals_stock_react_to_Q1_FY27_results\"><\/span><strong>How did the Krebs Biochemicals stock react to Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Krebs Biochemicals shares were trading higher at Rs 54.51 (+0.72%) on August 6, 2026, following the Krebs Biochemicals Q1 FY27 results announcement. Investors should consult a SEBI-registered financial advisor before acting on price movements.<\/p>\n<div class=\"faq-schema\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Krebs Biochemicals Q1 FY27 results: Revenue Rs 6 Cr (+27.42% YoY), PAT Rs 2.00 Cr (+53.33% YoY). Key highlights, financial analysis and FY27 outlook.<\/p>\n","protected":false},"author":36,"featured_media":190429,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-190431","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["190429"],"_edit_lock":["1786085205:36"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["81"],"rank_math_title":["Krebs Biochemicals Q1 FY27 Results: Revenue, PAT &amp; Key Highlights"],"rank_math_description":["Krebs Biochemicals Q1 FY27 results: Revenue Rs 6 Cr (+27.42% YoY), PAT Rs 2.00 Cr (+53.33% YoY). Key highlights, financial analysis and FY27 outlook."],"rank_math_focus_keyword":["Krebs Biochemicals Q1"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_edit_last":["36"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["34915"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/08\/krebs-biochemicals-q1-results-fy27-loss-2-crore.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/190431","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/36"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=190431"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/190431\/revisions"}],"predecessor-version":[{"id":190520,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/190431\/revisions\/190520"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/190429"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=190431"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=190431"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=190431"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}